Come eliminare il Clostridium difficile?

Come eliminare il Clostridium difficile?

Per trattare le infezioni da Clostridim difficile possono essere utilizzati diversi antibiotici. In caso di infezione primaria il trattamento prevede l'impiego di metronidazolo (nei casi di infezioni lievi), vancomicina o fidaxomicina.

Cosa provoca lo pseudomonas?

L'infezione da pseudomonas aeruginosa può portare a problemi di varia natura: respiratori (come polmonite), al sistema nervoso centrale (tra cui ascessi cerebrali e meningiti), all'orecchio (per esempio otiti), agli occhi (tra cui cheratite batterica e endoftalmite), a ossa e articolazioni (come l'osteomielite), ...

Come debellare il batterio pseudomonas?

L'infezione da pseudomonas aeruginosa viene curata con farmaci antimicrobici. I casi più complicati possono richiedere una terapia combinata basata sull'uso di due farmaci come un beta-lattamico e un aminiglicoside. Le cure sono adattate ai casi specifici.

What are the treatment options for Pseudomonas aeruginosa infections?

• Pseudomonas aeruginosa infections are generally treated with antibiotics. Unfortunately, in people exposed to healthcare settings like hospitals or nursing homes, Pseudomonas aeruginosa infections are becoming more difficult to treat because of increasing antibiotic resistance.

Is Pseudomonas aeruginosa infection more common in other countries?

• Highly antibiotic resistant Pseudomonas aeruginosa continue to be reported among travelers with infections who underwent surgery at several hospitals in Tijuana, Mexico. These infections highlight that resistant bacteria may be more common in other countries than in the United States.

What is the status of the Pseudomonas aeruginosa outbreak in Tijuana?

• Although an outbreak that primarily occurred at a single facility appears to be over, CDC continues to receive reports of antibiotic–resistant Pseudomonas aeruginosa infections in patients following surgery in Tijuana.

What is the mortality and morbidity associated with Pseudomonas infections?

• A total of 30 studies were included; infections related to carbapenems-resistant Pseudomonas spp. were reported in 18 (60%) studies. Globally, mortality ranged from 33 to 71% in patients with carbapenems-resistant Pseudomonas infections.